Declan Doogan - 10 Dec 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
10 Dec 2024
Net transactions value
$0
Form type
4
Filing time
12 Dec 2024, 19:58:31 UTC
Previous filing
12 Aug 2022
Next filing
03 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TENX Common Stock 2,274 10 Dec 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 10 Dec 2024 Common Stock 100,000 $5.94 Direct
holding TENX Stock Option (right tob buy) 4 10 Dec 2024 Common Stock 4 $3200.00 Direct F2
holding TENX Stock Option (right to buy) 4 10 Dec 2024 Common Stock 4 $992.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The aggregate number of shares of common stock were previously reported as 3,637,871, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
F2 These options were previously reported as covering 6,250 shares at an exercise price of $2.00 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
F3 These options were previously reported as covering 5,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.